Guard therapeutics

The Company conducts development and commercialization of treatment and diagnostics based on the alphamicroglobulin A1M protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer, guard therapeutics.

The presentation included an update on next development steps for the drug candidate RMC and progress within the preclinical development platform of new peptides intended for chronic treatment. A recording of the presentation is available on the company's website. The program began with the company's CEO, Tobias Agervald, providing a summary of the strategic considerations and positive feedback from the FDA that form the basis for the next development stages of RMC, including a planned Phase 2b study in open-heart surgery. Furthermore, the discussion also covered the way forward and the strategy for an upcoming pivotal Phase 3 study. Professor David Goldsmith, adjunct professor at King's College in London and a globally recognized Key Opinion Leader in nephrology, delivered a comprehensive presentation on irreversible loss of kidney function following open-heart surgery, highlighting the lack of specific treatment options despite the significant medical need.

Guard therapeutics

See the webcast. Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. Learn more about the clinical development of RMC RMC, our lead investigational drug, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue. Acute kidney injury is a large market. Guard Therapeutics announced that the U. Food and Drug Administration FDA granted RMC ROSgard Fast Track designation for reducing the risk of an irreversible loss of kidney function, initiation of kidney replacement therapy or death following open-chest cardiac surgery in patients who are at increased risk for acute kidney injury. Guard Therapeutics today announces that the first patient has been dosed in a Phase 1b clinical trial of the investigational drug RMC ROSgard in kidney transplantation. The company has thus achieved an important milestone by expanding the clinical development program to a second indication where RMC has the potential to protect against acute kidney injuries. Full study results are expected to be available in the first half of Financial calender Financial reports Share information Corporate governance General meetings. Press releases Event calender Analyses and presentations In media Subscribe. Latest Press Releases. Read more. Guard Therapeutics receives media attention after research view by Danske Bank Read more.

The overall goal is to identify new drug candidates tailored for the treatment of chronic diseases. Read more.

.

The presentation included an update on next development steps for the drug candidate RMC and progress within the preclinical development platform of new peptides intended for chronic treatment. A recording of the presentation is available on the company's website. New preclinical results from the company's peptide platform will also be presented. The next developmental step includes a phase 2b study with the aim of identifying an optimal dosage of RMC The phase 2b study is also expected to enable the most efficient design of a subsequent pivotal phase 3 study. Guard Therapeutics [GUARD], a biotechnology company specializing in kidney diseases, today announced further information regarding the development strategy for the investigational drug RMC An advisory meeting with the U. Food and Drug Administration FDA will be requested to explore dose optimization and the framework for a future registrational trial for the prevention of kidney injury in open-heart surgery. The development strategy is based on the recent top-line results of the Phase 2 AKITA study, which demonstrated statistically significant and clinically relevant long-term kidney-protective effects of RMC after open-heart surgery. The study aims to evaluate the kidney protective effect of the investigational drug RMC in relation to open heart surgery.

Guard therapeutics

See the webcast. Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. Learn more about the clinical development of RMC RMC, our lead investigational drug, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue. Acute kidney injury is a large market.

Nytimes mini

Peer analysis Key Information. The overall goal is to identify new drug candidates tailored for the treatment of chronic diseases. Show more Markets link Markets. Cancel Continue. Attachments: Guard Therapeutics presented development strategy and new preclinical results at RD Update. Maximum Entertainment AB. Add to Your Portfolio New portfolio. Any information that you receive via FT. Show more Opinion link Opinion. For further information, please contact:. Actions Add to watchlist Add to portfolio Add an alert.

Guard Therapeutics is a Swedish biotechnology company that develops novel therapies for diseases with a great medical need for more effective treatments. Our key therapeutic area is nephrology with a focus on acute kidney injuries. Our company is driven by a small team of world-leading scientific, medical and drug development expertise within nephrology.

Data as of Mar 01 Food and Drug Administration FDA granted RMC ROSgard Fast Track designation for reducing the risk of an irreversible loss of kidney function, initiation of kidney replacement therapy or death following open-chest cardiac surgery in patients who are at increased risk for acute kidney injury. Full study results are expected to be available in the first half of Furthermore, the discussion also covered the way forward and the strategy for an upcoming pivotal Phase 3 study. Show more Companies link Companies. The presentation included an update on next development steps for the drug candidate RMC and progress within the preclinical development platform of new peptides intended for chronic treatment. The Company conducts development and commercialization of treatment and diagnostics based on the alphamicroglobulin A1M protein. RMC, our lead investigational drug, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue. A1M is a candidate for different therapeutic and diagnostic u ses, such as alleviation of autoimmune diseases and stroke treatment. Actions Add to watchlist Add to portfolio Add an alert. Financial Times Close.